GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MoonLake Immunotherapeutics (NAS:MLTX) » Definitions » Enterprise Value

MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) Enterprise Value : $1,965.93 Mil (As of May. 23, 2024)


View and export this data going back to 2022. Start your Free Trial

What is MoonLake Immunotherapeutics Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, MoonLake Immunotherapeutics's Enterprise Value is $1,965.93 Mil. MoonLake Immunotherapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-61.01 Mil. Therefore, MoonLake Immunotherapeutics's EV-to-EBIT ratio for today is -32.22.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, MoonLake Immunotherapeutics's Enterprise Value is $1,965.93 Mil. MoonLake Immunotherapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-60.98 Mil. Therefore, MoonLake Immunotherapeutics's EV-to-EBITDA ratio for today is -32.24.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, MoonLake Immunotherapeutics's Enterprise Value is $1,965.93 Mil. MoonLake Immunotherapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. Therefore, MoonLake Immunotherapeutics's EV-to-Revenue ratio for today is .


MoonLake Immunotherapeutics Enterprise Value Historical Data

The historical data trend for MoonLake Immunotherapeutics's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MoonLake Immunotherapeutics Enterprise Value Chart

MoonLake Immunotherapeutics Annual Data
Trend Dec21 Dec22 Dec23
Enterprise Value
- 357.30 3,162.18

MoonLake Immunotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 791.82 2,235.56 2,621.90 3,162.18 2,624.63

Competitive Comparison of MoonLake Immunotherapeutics's Enterprise Value

For the Biotechnology subindustry, MoonLake Immunotherapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MoonLake Immunotherapeutics's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MoonLake Immunotherapeutics's Enterprise Value distribution charts can be found below:

* The bar in red indicates where MoonLake Immunotherapeutics's Enterprise Value falls into.



MoonLake Immunotherapeutics Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

MoonLake Immunotherapeutics's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

MoonLake Immunotherapeutics's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MoonLake Immunotherapeutics  (NAS:MLTX) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

MoonLake Immunotherapeutics's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1965.934/-61.012
=-32.22

MoonLake Immunotherapeutics's current Enterprise Value is $1,965.93 Mil.
MoonLake Immunotherapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-61.01 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

MoonLake Immunotherapeutics's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=1965.934/-60.98
=-32.24

MoonLake Immunotherapeutics's current Enterprise Value is $1,965.93 Mil.
MoonLake Immunotherapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-60.98 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

MoonLake Immunotherapeutics's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1965.934/0
=

MoonLake Immunotherapeutics's current Enterprise Value is $1,965.93 Mil.
MoonLake Immunotherapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MoonLake Immunotherapeutics Enterprise Value Related Terms

Thank you for viewing the detailed overview of MoonLake Immunotherapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) Business Description

Traded in Other Exchanges
Address
Dorfstrasse 29, Zug, CHE, 6300
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
Executives
Matthias Bodenstedt officer: Chief Financial Officer DORFSTRASSE 29, ZUG V8 6300
Bihua Chen 10 percent owner C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iv Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Ii, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Simon Sturge director DORFSTRASSE 29, ZUG V8 6300
Kristian Reich officer: Chief Scientific Officer DORFSTRASSE 29, ZUG V8 6300
Santos Da Silva Jorge director, officer: Chief Executive Officer DORFSTRASSE 29, ZUG V8 6300
Bvf Partners L P/il director, 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Andrew John Phillips director C/O CORMORANT ASSET MANAGEMENT, LLP, 200 CLARENDON STREET, FL 52, BOSTON MA 02116
Ramnik Xavier director DORFSTRASSE 29, ZUG V8 6300
Spike Loy director DORFSTRASSE 29, ZUG V8 6300
Kara Lassen director DORFSTRASSE 29, ZUG V8 6300

MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) Headlines

From GuruFocus